第四条 公司投资者关系管理工作体现公平、公正、公开原则，客观、真实、 准确、完整地介绍和反映公司的实际状况，避免过度宣传可能给投资者造成的误 导。 第五条 公司投资者关系管理工作应当严格遵守有关法律、行政法规、部门 规章、规范性文件、《创业板上市规则》、《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》和深圳证券交易所其他相关规定，不得 在投资者关系活动中以任何方式发布或者泄漏未公开重大信息。 第六条 公司指定董事会秘书担任投资者关系管理负责人，除非得到明确授 权并经过培训，公司其他董事、高级管理人员和员工应当避免在投资者关系活动 中代表公司发言。 普瑞眼科医院集团股份有限公司 投资者关系管理制度 第一章 总则 第一条 为规范公司投资者关系管理工作，进一步保护投资者的合法权益， 建立公司与投资者之间及时、互信的良好沟通关系，完善公司治理，根据《中华 人民共和国公司法》（以下称"《公司法》"）、《中华人民共和国证券法》（以下称 "《证券法》"）、《上市公司投资者关系管理工作指引》、《深圳证券交易所创业板 股票上市规则》（以下称"《创业板上市规则》"）、《深圳证券交易所上市公司自律 监管 ...

（一）独立聘请中介机构，对公司具体事项进行审计、咨询或者核查； 普瑞眼科医院集团股份有限公司 独立董事专门会议工作细则 第一章 总则 第一条 进一步完善普瑞眼科医院集团股份有限公司（以下称"公司"）法 人治理结构，促进独立董事有效履职，充分发挥独立董事在公司内部治理中的作用 ，维护公司整体利益，有效保障公司全体股东合法权益不受损害，公司根据《中华 人民共和国公司法》《上市公司治理准则》《深圳证券交易所上市公司自律监管指 引第2号——创业板上市公司规范运作》《上市公司独立董事管理办法》等相关法 律、行政法规和规范性文件以及《普瑞眼科医院集团股份有限公司章程》（以下称 "《公司章程》"）的有关规定，制定本工作细则。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及其主要 股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独立客 观判断关系的董事。 第三条 独立董事专门会议指全部由公司独立董事参加的，专门审议本工作细 则和相关法律法规、行政规章、自律性规定以及《公司章程》所规定的有关事项的 会议。 第二章 职责与权限 第四条 独立董事行使以下特别职权时应当经独立董事专门会议审议，并经全 ...

（陈凌云-已离任） 本人作为成都普瑞眼科医院集团股份有限公司（以下简称"公司"）第三 届董事会独立董事，在2024年度任职期间，严格按照《中华人民共和国公司法》 《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等法 律法规及《公司章程》《独立董事工作细则》等公司相关规定和要求，本着严 谨认真、勤勉尽责、诚实独立的原则，通过积极参加董事会和股东大会谨慎审 核公司提交的各项议案，发挥董事会专门委员会、独立董事专门会议的作用等 方式忠实履行了独立董事的职责和义务，切实维护了公司整体利益和全体股东 的合法权益。 成都普瑞眼科医院集团股份有限公司 独立董事2024年度述职报告 本人因在境内上市公司任职即将超过三家，经过慎重考虑，申请辞去公司 第三届董事会独立董事、审计委员会主任委员及提名委员会委员职务，自公司 于2024年5月23日召开2023年度股东大会选举产生新任独立董事之日起，本人不 再担任公司任何职务。 现将本人2024年度任职期间工作情况汇报如下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人陈凌云，1979年 ...

第一章总 则 第一条 为进一步完善普瑞眼科医院集团股份有限公司（以下简称"公司"）法人治理 结构，规范公司董事的选举，切实保障所有股东充分行使选择董事的权利，维护中小股东 利益，根据《中华人民共和国公司法》、《上市公司治理准则》、《深圳证券交易所上市公 司股东会网络投票实施细则》等法律、法规、规范性文件以及《普瑞眼科医院集团股份有 限公司章程》（以下简称"《公司章程》"）等公司治理制度的有关规定，制定本细则。 第二条 本细则所称累积投票制，是指公司股东会在选举董事时，有表决权的每一股份 与拟选出的董事人数相同的表决权，股东拥有的投票权数等于其所持有的股份数与该次股 东会应选董事人数的乘积。股东既可以用所有的投票权集中投票选举一位董事候选人，也 可以分散投票给多位董事候选人，董事由获得赞同投票数较多者当选。 第三条 公司在股东会选举两名或两名以上的董事时，应采用累积投票制并适用本实施 细则。 普瑞眼科医院集团股份有限公司 累积投票制实施细则 第三章 累积投票制的投票原则 公司股东会仅选举或变更一名独立董事、非独立董事时，不适用累积投票制。 第四条 在股东会上选举董事时，董事会应当在召开股东会的会议通知中，表明该 ...

普瑞眼科医院集团股份有限公司 内幕信息知情人登记管理制度 第一章 总则 第一条 为进一步完善普瑞眼科医院集团股份有限公司（下称"公司"） 内幕信息管理行为，加强内幕信息保密工作，维护信息披露的公平，根据《中华 人民共和国公司法》《中华人民共和国证券法》（以下称"《证券法》"）、《深 圳证券交易所创业板股票上市规则》《上市公司信息披露管理办法》《上市公司 监管指引第 5 号--上市公司内幕信息知情人登记管理制度》《深圳证券交易所上 市公司自律监管指引第 5 号——信息披露事务管理》等有关法律、法规及规范性 文件及《普瑞眼科医院集团股份有限公司章程》（以下称"《公司章程》"）、 《普瑞眼科医院集团股份有限公司信息披露管理制度》（下称"《公司信息披露 管理制度》"）的规定，结合公司实际情况，制定本制度。 第二条 董事会是公司内幕信息的管理机构，董事长为公司内幕信息保密 的主要负责人，董事会秘书具体负责内幕信息知情人登记管理工作。 第三条 公司证券部为公司内幕信息监督、管理、登记、披露及备案的日 常工作部门，具体负责公司内幕信息的日常管理工作。 对外报道传送的文件、电子存储设备等涉及内幕信息及信息披露内容的资 料，须 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥742,251,316.24, representing a year-on-year increase of 9.82% compared to ¥675,882,973.16 in the same period last year[5] - Net profit attributable to shareholders was ¥27,279,356.63, marking a significant increase of 61.18% from ¥16,924,936.43 in the previous year[5] - Basic and diluted earnings per share rose to ¥0.18, reflecting a growth of 63.64% compared to ¥0.11 in the same quarter last year[5] - Net profit for the current period was ¥28,776,862.83, representing a 51.5% increase from ¥19,042,640.10 in the previous period[20] - Earnings per share (EPS) for the current period was ¥0.18, compared to ¥0.11 in the previous period, indicating a 63.6% increase[21] Cash Flow - The net cash flow from operating activities increased by 54.87% to ¥194,676,885.40, up from ¥125,706,825.28 in Q1 2024[5] - Cash inflow from operating activities totaled ¥755,768,471.98, up from ¥679,993,838.41, marking an increase of 11.1%[23] - The net cash flow from operating activities was $194.68 million, an increase from $125.71 million in the previous period, reflecting a growth of 55%[24] - The net cash flow from investing activities improved by 33.81%, decreasing to -¥129,970,029.96 from -¥196,363,723.78 in the previous year[8] - The company reported a net cash outflow from investing activities of $129.97 million, an improvement from a net outflow of $196.36 million previously[24] Assets and Liabilities - Total assets at the end of Q1 2025 were ¥4,697,051,407.54, a 2.15% increase from ¥4,598,026,724.34 at the end of the previous year[5] - Current assets increased to CNY 1,042,289,047.66 from CNY 869,259,065.91, representing a growth of about 19.93%[15] - Total liabilities rose to ¥2,539,477,942.20, compared to ¥2,476,861,122.42, an increase of 2.5%[18] - Total equity attributable to shareholders reached ¥2,134,699,722.16, up from ¥2,101,497,552.89, a growth of 1.6%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,024[10] - The largest shareholder, Chengdu Puri Century Investment Co., Ltd., holds a 35.91% stake, amounting to 53,729,585 shares, with 20,541,200 shares pledged[10] - The company reported a total of 3,603,810 shares held by Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, making it one of the top shareholders[12] - The company has a total of 1,900,073 shares held by Industrial and Commercial Bank of China - Rongtong Health Industry Flexible Allocation Mixed Securities Investment Fund, indicating significant institutional interest[12] Operating Costs and Expenses - Total operating costs amounted to ¥690,187,707.10, up from ¥636,079,700.34, reflecting a rise of 8.5%[19] - Research and development expenses were ¥2,461,386.01, slightly up from ¥2,410,662.58, indicating a focus on innovation[20] - The company reported a decrease in tax expenses to ¥23,086,518.32 from ¥17,934,906.28, a reduction of 28.5%[20] - Cash outflows for employee compensation were $270.18 million, up from $237.42 million, representing an increase of 13.8%[24] Investment Activities - Total cash outflow from investing activities amounted to $299.32 million, compared to $196.39 million previously, indicating a significant increase in investment spending[24] - The cash inflow from investment activities was $169.35 million, significantly higher than $25.50 million in the previous period, marking a substantial increase[24]

Financial Performance - The company's operating revenue for 2024 was approximately ¥2.68 billion, a decrease of 1.46% compared to ¥2.72 billion in 2023[25]. - The net profit attributable to shareholders for 2024 was approximately -¥101.86 million, representing a decline of 138.02% from ¥267.91 million in 2023[25]. - The cash flow from operating activities for 2024 was approximately ¥382.43 million, down 37.76% from ¥614.46 million in 2023[25]. - The basic earnings per share for 2024 was -¥0.68, a decrease of 137.99% compared to ¥1.79 in 2023[25]. - Total assets at the end of 2024 were approximately ¥4.60 billion, a decrease of 4.51% from ¥4.82 billion at the end of 2023[25]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥2.10 billion, down 8.30% from ¥2.29 billion at the end of 2023[25]. - The company reported a quarterly operating revenue of ¥675.88 million in Q1 2024, with a decline in revenue to ¥541.58 million in Q4 2024[27]. - The net profit attributable to shareholders in Q4 2024 was -¥117.70 million, following a positive net profit in the first two quarters[27]. - The company experienced a significant drop in net profit after deducting non-recurring gains and losses, with a figure of -¥85.22 million for 2024 compared to ¥197.81 million in 2023[25]. - The weighted average return on equity for 2024 was -4.65%, a decrease of 16.86% from 12.21% in 2023[25]. - The company reported a non-operating loss of approximately ¥16.64 million in 2024, a significant decrease from a profit of ¥70.1 million in 2023[32]. Market and Industry Trends - In 2024, the company's revenue from refractive and optical projects experienced a slight decline due to a slowdown in overall demand and intensified industry competition[4]. - The implementation of national centralized procurement policies for cataract artificial lenses starting May 2024 has put pressure on the company's cataract project revenue[4]. - The company is positioned in a growing ophthalmic medical service market, with a significant increase in myopia prevalence from 39.2% in 2016 to 47.1% in 2020[36]. - The cataract surgery penetration rate in China remains low despite rapid growth in the number of surgeries over the past decade, indicating room for further market expansion[37]. - The overall myopia rate among children and adolescents in China is 51.9%, highlighting a critical need for effective prevention measures[36]. - The National Health Commission's "14th Five-Year" plan aims for a 90% coverage rate for eye health checks among children aged 0-6 by 2025, which will enhance market opportunities[37]. - The market for myopia prevention products is expected to grow as public awareness increases, with products like orthokeratology lenses gaining traction[36]. Strategic Initiatives and Investments - The company has accelerated its investment expansion, opening multiple new hospitals in 2022, 2023, and 2024, including locations in Kunming, Nanchang, and Shanghai[5][6]. - New hospitals are currently in the market cultivation phase, leading to slower revenue growth and increased operational costs, including depreciation and labor expenses[6]. - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[7]. - The company is focusing on enhancing service capabilities in pediatric myopia prevention and elderly eye disease treatment as part of its strategic initiatives[37]. - The company is committed to adapting to the evolving healthcare landscape, leveraging technological advancements to meet the rising demand for personalized eye care solutions[35]. - The company is actively responding to the national strategy for myopia prevention and control, establishing a personalized vision management system[56]. - The company has established a "full-cycle eye health service system" focusing on pre-diagnosis, diagnosis, and post-diagnosis management[47]. Technological Advancements - AI technology is rapidly penetrating the eye care sector, optimizing diagnosis and treatment processes, and facilitating a shift towards intelligent and precise medical services[44]. - AI algorithms are being utilized for real-time monitoring of eye pressure and personalized rehabilitation plans for cataract patients, significantly improving post-operative satisfaction[45]. - The introduction of AI in operational areas is enhancing scheduling, cost monitoring, and patient follow-up, thereby increasing operational efficiency and patient compliance[45]. - The company is advancing its digital transformation by integrating AI, internet, and big data technologies to reconstruct service models and business processes[112]. - The company plans to create an integrated online and offline service loop, enhancing patient convenience through upgraded internet hospital functionalities and AI-driven customer service[113]. Research and Development - The company published 103 academic papers and participated in the formulation of 13 industry standards in 2024, enhancing its academic influence[58]. - The company is conducting research on the effectiveness and safety of CLASS surgery for different stages of glaucoma[71]. - A new digital corneal reshaping lens is being developed to improve vision in patients with high myopia[72]. - Clinical studies are ongoing to evaluate the effectiveness of new surgical techniques for retinal detachment and chronic dacryocystitis[72]. - The number of R&D personnel increased to 93 in 2024, up from 76 in 2023, representing a growth of 22.37%[74]. - The company is investing in new product development, with a budget allocation of 500 million for R&D in the upcoming fiscal year[138]. Corporate Governance and Compliance - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal regulations[127]. - The company has revised several management systems to enhance information disclosure, aiming for accurate and timely communication with investors[127]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[129]. - The company has a complete and clear ownership of assets, including land, properties, medical facilities, trademarks, and patents[129]. - The company has established an independent financial accounting system and maintains separate bank accounts from its controlling shareholders[129]. - The company has not faced any regulatory criticism regarding information disclosure during the reporting period[127]. Social Responsibility and ESG Initiatives - The company invested over 5 million yuan in social welfare initiatives, benefiting over 100,000 people in rural areas[176]. - The company provided over 21,000 pairs of free glasses and conducted more than 250 free surgeries for underprivileged children and elderly individuals[176]. - The company actively adheres to environmental regulations and has not faced any administrative penalties related to environmental issues during the reporting period[174]. - The company emphasizes the integration of ESG principles into its corporate culture and daily operations[175]. - The company is committed to sustainable development and social responsibility, balancing environmental, economic, and social values[175]. Shareholder Relations and Financial Management - The company announced a cash dividend of RMB 4.00 per 10 shares, totaling RMB 59,545,512.40, which accounts for 22.23% of the net profit attributable to shareholders for the reporting period[123]. - The company completed the acquisition of Dali Optometry Hospital in December 2024, enhancing its market share in the Yunnan region[120]. - The company has established a three-year shareholder return plan to balance performance growth with shareholder returns, promoting a sustainable development model[116]. - The company will not distribute profits in 2024 due to anticipated losses and to ensure sufficient funds for long-term development[164]. - The company has approved a plan to stabilize its stock price for three years post-IPO, triggered if the stock price closes below the audited net asset value per share for 20 consecutive trading days[193].

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-008 特此公告。 成都普瑞眼科医院集团股份有限公司 董事会 二〇二五年四月八日 成都普瑞眼科医院集团股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）于近日收到国泰海通 证券股份有限公司（以下简称"国泰海通"）出具的《关于更换持续督导保荐代表人 的函》。国泰海通作为公司首次公开发行股票并在创业板上市的保荐机构，原指派田 卓玲女士和朱玉峰先生担任保荐代表人，负责保荐工作及持续督导工作，持续督导期 至2025年12月31日。 原保荐代表人朱玉峰先生因工作安排原因，无法继续从事对公司的持续督导工作。 为保证持续督导工作的有序进行，国泰海通现委派保荐代表人李沁杭先生（简历详见 附件）接替朱玉峰先生继续履行持续督导工作。 本次变更后，公司首次公开发行股票的持续督导保荐代表人为田卓玲女士和李沁 杭先生，持续督导期至中国证券监督管理委员会和深圳证券交易所规定的持续督导义 务结束为止。 本次变更持续督导保荐代表人的 ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-011 成都普瑞眼科医院集团股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）于2025年4月7 日召开第三届董事会第三十次会议和第三届监事会第二十一次会议，分别审议通 过了《关于使用部分闲置募集资金暂时补充流动资金的议案》，同意公司使用总 额不超过人民币25,000万元的闲置募集资金暂时补充流动资金，使用期限为自第 三届董事会第三十次会议审议通过之日起不超过12个月，到期归还至募集资金专 用账户。国泰海通证券股份有限公司（以下简称"保荐机构"）对该事项出具了 无异议的核查意见，本事项无需提交股东大会审议。现将相关情况公告如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意成都普瑞眼科医院股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]587号）同意注册，公司首次公开 发行人民币普通股（A股）股票37,404,762股，每股面值人民币1.00元，每股发 行价 ...

国泰海通证券股份有限公司 关于成都普瑞眼科医院集团股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通证券"或"保荐机构"）作为 成都普瑞眼科医院集团股份有限公司（以下简称"普瑞眼科"或"公司"）首次公开 发行股票并在创业板上市持续督导保荐机构，根据《证券发行上市保荐业务管理 办法》、《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》、《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第2号-创业板上市公司规范运作》等有关规定，对公司使用部 分闲置募集资金暂时补充流动资金的事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意成都普瑞眼科医院股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]587 号）同意注册，成都普瑞眼科医 院股份有限公司首次公开发行人民币普通股（A 股）股票 37,404,762 股，每股面 值人民币 1.00 元，每股发行价格为 33.65 元，募集资金总额为 1,258,670,241.30 元，扣除发行费用（含税）后，实际 ...